WuXi Biologics: Business Overview, Financials & Competitive Analysis
WuXi Biologics scores 7/10 on the AskCyborg Cyborg Score (Strong). Leading global biologics CRDMO with strong growth, substantial backlog, and technological innovation, though geopolitical risks warrant monitoring. WuXi reported solid 2024 results with 9.6% revenue growth and 14.4% adjusted EBITDA growth to RMB7,999.3 million. The company was awarded CDMO of the Year at the Asia Pacific Biologics CDMO Excellence Awards.
What is WuXi Biologics's industry? WuXi Biologics (wuxibiologics.com) operates in Biopharmaceutical Contract Research, Development & Manufacturing (CRDMO/CDMO). AskCyborg classifies WuXi Biologics under Biopharmaceutical Contract Research, Development & Manufacturing (CRDMO/CDMO) in its company registry.
WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development. The company operates a compreh...
Cyborg Score thesis
Leading global biologics CRDMO with strong growth, substantial backlog, and technological innovation, though geopolitical risks...
Read the full analyst-debate transcript →Get the Latest WuXi Biologics Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeWuXi Biologics Overview
Pro stress-test →WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development. The company operates a comprehensive end-to-end platform spanning from molecule discovery through commercial manufacturing, servicing global biopharmaceutical clients across discovery, development, and manufacturing.
Strategic Profile
Pro stress-test →WuXi Biologics reported 2024 revenue growth of 9.6% YoY to RMB 18,675.4 million, driven by non-COVID revenue up 13.1%. The company maintains a total backlog of US$18.5 billion and has strengthened its global presence with facility expansions in Ireland, Singapore, and the U.S. The company's positioning as a leading global CRDMO with proprietary antibody platforms positions it favorably within the high-growth biologics outsourcing market.
Competitive Landscape
Pro stress-test →WuXi Biologics competes within the global CRDMO market against major players including Lonza, Samsung BioLogics, and Fujifilm Diosynth. The company received CDMO Leadership Awards for the eighth consecutive year in 2025 in the "Biologics - Global" category, demonstrating sustained competitive positioning. The company's proprietary antibody platforms (WuXiBody, WuXia, WuXiUP) and extensive manufacturing footprint provide competitive advantages in service breadth and capacity.
Industry Context
WuXi Biologics operates in Biopharmaceutical Contract Research, Development & Manufacturing (CRDMO/CDMO).
Key facts
Founded: 2010 · Headquarters: Wuxi, China · Employees: 10,000 · Revenue: $2.55B (RMB 18.675B in 2024)